Key points are not available for this paper at this time.
A LLOGENEIC BONE MARROW transplantation (BMT) is an effective treatment for hematologic malignancies.' More than 5,000 transplants are performed yearly worldwide. The increasing use of human leukocyte antigen (HLA) nonidentical donors, and HLA-matched unrelated donors will assure the continued growth in the use of this therapeutic modality.'
Giralt et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: